Cytokines Involved in the Progression of Multiple Myeloma

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1993 Apr 1

PMID 8467562

Citations 21

Authors

F Merico

L Bergui

M G Gregoretti

P Ghia

G Aimo

I J Lindley

F Caligaris-Cappio

Affiliations

Soon will be listed here.

Abstract

We have investigated which of the cytokines that are relevant in the in vitro growth of multiple myeloma (MM) malignant plasma cells are actually produced in vivo by MM patients. To this end, we have measured the levels of IL-1 beta, IL-3, IL-4, IL-6, IL-7, IL-8 and tumour necrosis factor-alpha (TNF-alpha) both in sera and in the supernatant of bone marrow (BM) stromal cell cultures from patients with MM and monoclonal gammopathy of undetermined significance (MGUS). The significance of our findings is three-fold. First, IL-6 and IL-8 are produced by MM BM stromal cells, while IL-1 beta, TNF-alpha, IL-4 and IL-7 are not. Second, IL-3 is the only cytokine consistently raised in serum samples: we have also detected low levels of serum IL-6 in a minority of cases, usually in advanced stage of the disease. Third, MM BM stromal cells are active IL-6 and IL-8 producers, while both normal and MGUS BM stromal cells are low producers, thus suggesting that in the BM of MM a number of environmental cells, that would normally be quiescent, are instead activated and that, in MM, activated BM stromal cells play an active role in supporting the progressive expansion of the B cell clone.

Citing Articles

Mesenchymal stromal cell senescence in haematological malignancies.

Plakhova N, Panagopoulos V, Vandyke K, Zannettino A, Mrozik K Cancer Metastasis Rev. 2023; 42(1):277-296.

PMID: 36622509 DOI: 10.1007/s10555-022-10069-9.

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia.

Allegra A, Tonacci A, Musolino C, Pioggia G, Gangemi S Front Immunol. 2021; 12:738915.

PMID: 34759921 PMC: 8573331. DOI: 10.3389/fimmu.2021.738915.

Regulatory T-Cells and Multiple Myeloma: Implications in Tumor Immune Biology and Treatment.

Hadjiaggelidou C, Katodritou E J Clin Med. 2021; 10(19).

PMID: 34640606 PMC: 8509132. DOI: 10.3390/jcm10194588.

Pathogenesis and treatment of multiple myeloma bone disease.

Hiasa M, Harada T, Tanaka E, Abe M Jpn Dent Sci Rev. 2021; 57:164-173.

PMID: 34611468 PMC: 8477206. DOI: 10.1016/j.jdsr.2021.08.006.

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib.

Robak P, Weglowska E, Drozdz I, Mikulski D, Jarych D, Ferlinska M Mediators Inflamm. 2020; 2020:1835836.

PMID: 32587468 PMC: 7294367. DOI: 10.1155/2020/1835836.

References

Nemunaitis J, ANDREWS D, Mochizuki D, Lilly M, Singer J . Human marrow stromal cells: response to interleukin-6 (IL-6) and control of IL-6 expression. Blood. 1989; 74(6):1929-35. View

Klein B, Bataille R . Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am. 1992; 6(2):273-84. View

Nakamura M, Merchav S, Carter A, Ernst T, Demetri G, Furukawa Y . Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989; 143(11):3543-7. View

Bataille R, Jourdan M, Zhang X, Klein B . Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989; 84(6):2008-11. PMC: 304085. DOI: 10.1172/JCI114392. View

Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman G . IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol. 1990; 144(11):4226-30. View

Zhang X, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P . Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood. 1990; 76(12):2599-605. View

Jernberg H, Pettersson M, Kishimoto T, Nilsson K . Heterogeneity in response to interleukin 6 (IL-6), expression of IL-6 and IL-6 receptor mRNA in a panel of established human multiple myeloma cell lines. Leukemia. 1991; 5(3):255-65. View

Kodama H, Nose M, Niida S, Yamasaki A . Essential role of macrophage colony-stimulating factor in the osteoclast differentiation supported by stromal cells. J Exp Med. 1991; 173(5):1291-4. PMC: 2118848. DOI: 10.1084/jem.173.5.1291. View

Caligaris-Cappio F, Bergui L, Gregoretti M, Gaidano G, Gaboli M, Schena M . 'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991; 77(12):2688-93. View

10.

Ludwig H, Nachbaur D, Fritz E, Krainer M, HUBER H . Interleukin-6 is a prognostic factor in multiple myeloma. Blood. 1991; 77(12):2794-5. View

11.

Klein B, Wijdenes J, Zhang X, Jourdan M, Boiron J, BROCHIER J . Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991; 78(5):1198-204. View

12.

Peichl P, Ceska M, Effenberger F, Haberhauer G, Broell H, Lindley I . Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol. 1991; 34(3):333-9. DOI: 10.1111/j.1365-3083.1991.tb01554.x. View

13.

Mundy G, Raisz L, Cooper R, Schechter G, Salmon S . Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med. 1974; 291(20):1041-6. DOI: 10.1056/NEJM197411142912001. View

14.

Durie B, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3):842-54. DOI: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. View

15.

Bertolini D, Nedwin G, Bringman T, Smith D, Mundy G . Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature. 1986; 319(6053):516-8. DOI: 10.1038/319516a0. View

16.

Garrett I, Durie B, Nedwin G, Gillespie A, Bringman T, Sabatini M . Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med. 1987; 317(9):526-32. DOI: 10.1056/NEJM198708273170902. View

17.

Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K . Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988; 332(6159):83-5. DOI: 10.1038/332083a0. View

18.

Avanzi G, Lista P, Giovinazzo B, Miniero R, Saglio G, Benetton G . Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol. 1988; 69(3):359-66. DOI: 10.1111/j.1365-2141.1988.tb02374.x. View

19.

Stashenko P, Dewhirst F, Rooney M, Desjardins L, Heeley J . Interleukin-1 beta is a potent inhibitor of bone formation in vitro. J Bone Miner Res. 1987; 2(6):559-65. DOI: 10.1002/jbmr.5650020612. View

20.

Klein B, Zhang X, Jourdan M, Content J, Houssiau F, Aarden L . Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989; 73(2):517-26. View